CDTRP 2026 Research Innovation Grant Competition Results

CDTRP is thrilled to announce the results of the CDTRP 2026 Research Innovation Grant Competition, made possible through our partnership with various esteemed organizations. We are proud to showcase all of the exciting projects that have been funded in this year’s competition.

We would like to extend our warmest congratulations to Dr. Julian Hercun and his team for being awarded the CDTRP UdeM Research Innovation Grant. We wish them all the best as they embark on their innovative project!

“I warmly congratulate Dr. Julian Hercun on winning the CDTRP Innovation Grant in the 2026 competition for his project entitled “Evaluation of the gut–liver axis in post-transplant recurrence of primary sclerosing cholangitis”.

This project is perfectly aligned with the mission of the Université de Montréal Transplant Program to improve the care of transplant donors, families and patients through research and clinical innovation. We are proud to contribute to the CDTRP grant competitions and thus participate in transplantation and organ donation research in Canada.”

Ekat Kritikou, Vice-Dean, Research and Development, Faculty of Medicine, Université de Montréal

CDTRP UdeM Research Innovation Grant : Dr. Julian Hercun

Project Title: Evaluation of the gut–liver axis in post-transplant recurrence of primary sclerosing cholangitis

Main affiliation: Centre hospitalier de l’Université de Montréal

Theme: 5 – Restore Long-Term Health

Lay Abstract

Primary sclerosing cholangitis (PSC) causes chronic inflammation of the bile ducts. PSC is often seen with inflammatory bowel disease, which impacts the gut. PSC has no cure and a liver transplant is often the only solution. In some cases, PSC can even return on the transplanted liver. In this study, we are trying to understand if changes in the gut can cause PSC to return. This trial will focus on two components of the gut : bacteria, called the microbiome, and bile acids.

This study will take place at the Centre hospitalier de l’Universite de Montreal (CHUM). Adult patients with a liver transplant for PSC can be candidates. A one-time visit will combine imaging of the liver (with MRI) and blood and stool tests. The tests will check for microbiome and bile acid composition. The results will compare people with and without recurrence of PSC on the MRI. To see if this has an impact on quality of life, a questionnaire will look at PSC symptoms.

This study will identify if there are changes in the gut in PSC recurrence after transplant. This can be a target for PSC treatment in the future. The findings of this study will help researchers understand why PSC recurs. The ultimate goal is to improve quality of life after liver transplant in PSC.